LEO Pharma Announced CHE Awareness Campaign

LEO Pharma Inc. has launched Talk to the Hand, a disease awareness campaign for healthcare providers that highlights the risk factors, symptoms, and physical and emotional impact of chronic hand eczema (CHE)—a debilitating skin condition for which there are currently no FDA approved treatments. 

“As a dermatologist, I’ve seen first-hand the impact CHE has on patients. Many patients with moderate-to-severe CHE say holding, or even just touching, everyday objects can be difficult and frustrating,” Omar Noor, MD, FAAD, Co-Owner of Rao Dermatology, said in a press release. “Our hands are a part of everything we do and who we are—it is essential for healthcare providers to understand that CHE is not just atopic dermatitis of the hands. We need to recognize the unique challenges of CHE so that we can more effectively diagnose and care for those across the US living with this condition.”

The Talk to the Hand campaign highlights the impact to patients and provides illustrations that explain the impact of CHE through www.TalkCHE.com. Healthcare providers can learn more about CHE risk factors and symptoms and stay up to date on the latest CHE news to facilitate better conversations with their patients and help them access information about treatment options.

“LEO Pharma is proud to launch the Talk to the Hand campaign as part of our commitment to make a fundamental difference for patients living with skin disease,” Brian Hilberdink, EVP and President, Region North America, LEO Pharma, said in the press release. “We are committed to improving the standard of care in medical dermatology and patient voice is an essential part of the equation. Our hope is that this campaign will help healthcare providers more easily recognize and diagnose CHE and provide patients with the answers they need to manage their skin condition and take back their lives.”

Kristin Belleson, President and CEO National Eczema Association (NEA), said in the press release that the NEA is excited about the campaign helping to shed light on the unmet need for diagnosis and care for patients living with CHE.

“We are optimistic that through continued research and heightened awareness, we will find better and faster ways to determine the root cause of CHE to improve patient outcomes,” Belleson said.